The integrated pharmacomicrobiomics analysis revealed systemic metabolic reprogramming through blood circulation as a key mechanism: ETO first altered plasma metabolites (particularly TCA cycle intermediates and sphingolipids), creating a tumor-suppressive microenvironment. Here, RUNX1T1 is linked to neoplasm.